Annual Secretarial Compliance Report for the year ended March 31, 2026
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gland Pharma Limited has submitted its Annual Secretarial Compliance Report for FY 2025-26, as mandated under SEBI Regulation 24A. The report was prepared by RVR & Associates, Company Secretaries, who examined the company's compliance with key SEBI regulations including LODR, SAST, Insider Trading, Share Based Employee Benefits, and Depositories regulations. The secretarial auditor conducted a comprehensive review of documents, filings, website disclosures, and other relevant records. The key finding is that the company has achieved full compliance across all 13 checked parameters, with no deviations, violations, or penalties reported. No non-compliances were observed in any SEBI regulation, circular, or guidance note. The report confirms proper adoption of policies, timely disclosures, preservation of documents, and compliance with secretarial standards.
This clean compliance report is positive for shareholders as it confirms the company maintained proper corporate governance standards with no regulatory violations or penalties during the fiscal year, which supports investor confidence.